Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chagas Disease (American Trypanosomiasis)-Pipeline Review, H1 2015

Chagas Disease (American Trypanosomiasis)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chagas Disease (American Trypanosomiasis)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chagas Disease (American Trypanosomiasis)-Pipeline Review, H1 2015', provides an overview of the Chagas Disease (American Trypanosomiasis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chagas Disease (American Trypanosomiasis) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Chagas Disease (American Trypanosomiasis) Overview 8

Therapeutics Development 9

Pipeline Products for Chagas Disease (American Trypanosomiasis)-Overview 9

Pipeline Products for Chagas Disease (American Trypanosomiasis)-Comparative Analysis 10

Chagas Disease (American Trypanosomiasis)-Therapeutics under Development by Companies 11

Chagas Disease (American Trypanosomiasis)-Therapeutics under Investigation by Universities/Institutes 12

Chagas Disease (American Trypanosomiasis)-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Chagas Disease (American Trypanosomiasis)-Products under Development by Companies 15

Chagas Disease (American Trypanosomiasis)-Products under Investigation by Universities/Institutes 16

Chagas Disease (American Trypanosomiasis)-Companies Involved in Therapeutics Development 17

Anacor Pharmaceuticals, Inc. 17

Eisai Co., Ltd. 18

Grupo Praxis Pharmaceutical SA 19

Merck & Co., Inc. 20

Panacela Labs, Inc. 21

Sanofi 22

Seek 23

Chagas Disease (American Trypanosomiasis)-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

benznidazol-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

chagas disease vaccine-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

chagas disease vaccine-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

chagas disease vaccine-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Cz-007-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Cz-008-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drugs for Chagas Disease-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

E-1224-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

EPLBS-1246-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

EPLBS-967-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

fexinidazole-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

K-777-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

LH-7-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Monoclonal Antibody for Chagas-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

NEU-321-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

posaconazole-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecules for Chagas Disease-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecules for Chagas Disease-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecules for Chagas Disease-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules for Chagas Disease-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules for Infectious Diseases-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules for Protozoal Infections-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

VNI-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

XELRYX-3-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Chagas Disease (American Trypanosomiasis)-Recent Pipeline Updates 63

Chagas Disease (American Trypanosomiasis)-Dormant Projects 65

Chagas Disease (American Trypanosomiasis)-Discontinued Products 66

Chagas Disease (American Trypanosomiasis)-Product Development Milestones 67

Featured News & Press Releases 67

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 67

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 67

May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 69

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 70

Mar 12, 2012: DNDi Receives 2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2015 9

Number of Products under Development for Chagas Disease (American Trypanosomiasis)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Chagas Disease (American Trypanosomiasis)-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 17

Chagas Disease (American Trypanosomiasis)-Pipeline by Eisai Co., Ltd., H1 2015 18

Chagas Disease (American Trypanosomiasis)-Pipeline by Grupo Praxis Pharmaceutical SA, H1 2015 19

Chagas Disease (American Trypanosomiasis)-Pipeline by Merck & Co., Inc., H1 2015 20

Chagas Disease (American Trypanosomiasis)-Pipeline by Panacela Labs, Inc., H1 2015 21

Chagas Disease (American Trypanosomiasis)-Pipeline by Sanofi, H1 2015 22

Chagas Disease (American Trypanosomiasis)-Pipeline by Seek, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Chagas Disease (American Trypanosomiasis) Therapeutics-Recent Pipeline Updates, H1 2015 63

Chagas Disease (American Trypanosomiasis)-Dormant Projects, H1 2015 65

Chagas Disease (American Trypanosomiasis)-Discontinued Products, H1 2015 66

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2015 9

Number of Products under Development for Chagas Disease (American Trypanosomiasis)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals, Inc.

Eisai Co., Ltd.

Grupo Praxis Pharmaceutical SA

Merck & Co., Inc.

Panacela Labs, Inc.

Sanofi

Seek

Chagas Disease (American Trypanosomiasis) Therapeutic Products under Development, Key Players in Chagas Disease (American Trypanosomiasis) Therapeutics, Chagas Disease (American Trypanosomiasis) Pipeline Overview, Chagas Disease (American Trypanosomiasis) Pipeline, Chagas Disease (American Trypanosomiasis) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com